<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01068041</url>
  </required_header>
  <id_info>
    <org_study_id>PH-CP016</org_study_id>
    <nct_id>NCT01068041</nct_id>
  </id_info>
  <brief_title>Effects of PH3 in Diabetic Nephropathy</brief_title>
  <acronym>PH3</acronym>
  <official_title>Effects of PH3 in Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PhytoHealth Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PhytoHealth Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this clinical study is to evaluate the effectiveness and safety of
      PH3 for patients with diabetic nephropathy.

      The secondary objectives are to identify the optimal dosage for subsequent studies and to
      provide basis for the next confirmatory study in study design, endpoints, and study
      methodologies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Albumin/Creatinine Ratio (UACR)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine Albumin Serum Creatinine and the estimated GFR (glomerular filtration rate) HbA1c</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250mg active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500mg active ingredient</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1000mg active ingredient</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PH3</intervention_name>
    <description>Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and Females between 18 and 70 years of age with type 1 or type 2 diabetes

          2. Sitting blood pressure of &lt;=140/90 mm Hg

          3. Serum creatinine &lt;=2.0 mg/dL

          4. Urinary albumin: creatinine ratio between 30 mg/g to 1000 mg/g creatinine (of the
             first urine sample of the day)

          5. Hemoglobin A1c &lt;=8%

          6. Women of child-bearing potential must test negative in a pregnancy test and take
             contraception measures to prevent pregnancy and can not be breast-feeding

          7. Voluntary written consent to participate in this study

        Exclusion Criteria:

          1. History of major cardiovascular or cerebrovascular events within 6 months prior to
             screening

          2. History of cancer

          3. Receiving chronic nonsteroidal anti-inflammatory therapy

          4. History of diabetic ketoacidosis

          5. Has clinically significant deviation from normal physical examination findings that,
             in the principal investigator's judgment, may interfere with the study evaluation or
             affect subject safety

          6. Has participated in other investigational trials within 28 days prior to study
             enrollment

          7. Has taken herbal medical treatment as prescription medication and/or over-the- counter
             medication, within 28 days prior to study enrollment.

          8. Has known allergy to the study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wu Chang Yang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taipei Veterans General Hospital, Taiwan</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yi-Jen Hung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tri-Service General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huey-Herng Sheu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Taichung Veterans General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2010</study_first_submitted>
  <study_first_submitted_qc>February 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <last_update_submitted>November 3, 2015</last_update_submitted>
  <last_update_submitted_qc>November 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

